Summary
Gilead Sciences, Inc. announced the successful completion of its acquisition of CymaBay Therapeutics, Inc. on March 22, 2024. The acquisition was executed through a tender offer that commenced on February 23, 2024, with Gilead offering $32.50 per share in cash. The tender offer successfully secured approximately 77.3% of CymaBay's outstanding shares, exceeding the minimum tender condition. Following the tender offer, Gilead proceeded with a merger under Delaware law, converting all remaining eligible shares not already acquired in the tender offer into the right to receive the same $32.50 per share in cash. The total aggregate consideration paid by Gilead for this acquisition amounts to approximately $4.3 billion. This strategic move is expected to bolster Gilead's pipeline and therapeutic offerings, particularly in areas where CymaBay has a presence.
Key Highlights
- 1Gilead Sciences, Inc. has successfully completed the acquisition of CymaBay Therapeutics, Inc.
- 2The acquisition was finalized on March 22, 2024.
- 3The purchase price was $32.50 per share in cash.
- 4A tender offer was launched on February 23, 2024, and secured approximately 77.3% of CymaBay's outstanding shares.
- 5The total aggregate consideration paid for the acquisition was approximately $4.3 billion.
- 6The merger was completed on March 22, 2024, following the successful tender offer.
- 7The transaction is expected to be a strategic addition to Gilead's portfolio.